

ANATARA LIFESCIENCES LTD

Company Overview

PRIVATE & CONFIDENTIAL



Candour
Advisory

Corporate Profile



Type	Listed Public Company
ASX Code	ANR.ASX
Shares on Issue	~168m
Share Price (23/01/24)	-\$0.026
Market Capitalisation	A\$4.37m
Cash (December 31 2023)	\$1.034m

Company Overview

Anatara Lifesciences Ltd (ASX:ANR) (“Anatara” or “the Company”) is focused on the validation and commercialisation of innovative, evidence-based gastrointestinal treatments.

The Company has delivered positive clinical results in Stage 1 of a Phase II IBS trial for its primary patent-protected product, GaRP. This product has the potential to satisfy a significant unmet need in the market.



Gastrointestinal ReProgramming (GaRP)

Anatara's primary product, GaRP is a patent pending multi-component, multi coated complementary medicine containing proprietary Bromelain, Menthol, Vitamin D, Threonine & Butyrate.



- **Genuine Mechanism of Action understood:** Developing a clinically validated, evidence-based treatment for IBS.
- **Patent Pending:** Scientifically formulated treatment with clear intellectual property surrounding components & coating for delivery to specific targets in the gastrointestinal tract.
- **GMP Product:** Low cost of production, GMP manufactured product, designed for mass market.
- **Effective Relief:** Reduces IBS-SSS Score by 56% setting treatment apart from competitors.
- **Safe Natural Components:** Well-understood GRAS 'generally regarded as safe' components.
- **OTC Everyday Option:** OTC product fits the consumer demand for IBS treatment.



Anatara Investment Highlights

Pivotal Clinical Trial for Irritable Bowel Syndrome

- Stage 1 (61 patients) proven to be safe with a strong reduction in IBS-SSS scores of ~56% vs 36% for placebo at 8 weeks. Also significant reductions recorded in Anxiety & Depression scores.
- Positive Stage 1 results announced 3Q CY2023, Stage 2 (full results) anticipated 2Q CY2024.

Significant Market Opportunities

- Digestive Health Market to be valued at **US\$23.4B** in 2030 with a CAGR of **8.1%**.

Significant unmet medical need

- Treatments for IBS/IBD are often not effective in controlling symptoms, only 15-20% of patients are 'very satisfied' with their treatment options, this includes both OTC and prescription items.

GaRP has significant IBS potential

- GaRP addresses the underlying factors of many GIT disorders, providing multi-faceted symptomatic relief while rejuvenating the tract.

Assessing commercial options for GaRP

- Actively assessing potential commercial partners for GaRP.
- Initiated assessment of whether Stage 1 results will satisfy claims for GaRP to be Listed through the AUST L Nos pathway.

GaRP technology to provide a pipeline of products

- Potential indications for GaRP include Inflammatory Bowel Disease (IBD), Paediatric indications & Functional Dyspepsia.
- All present significant market opportunities with unmet needs.

Clear commercialisation strategy

- **Direct to Patient E-Commerce sales** once product registered in Australia via TGA Aust-L(A).
- **Partnering** to leverage established market position and infrastructure. International partners anticipated post Stage 2 success.



The Importance of Gut Health

Gut Health promotes General Wellbeing:


- The gut microbiome and the brain communicate with each other through a complex network of nerves, hormones, and organic messengers which are critical to general wellbeing.
- There is increasing awareness of the importance of gut microbiome health which relates to a range of diseases including cardiovascular disease, autoimmune disorders and psychological well-being.

Further Benefits of Gut Health:

- Enhanced Nutrient Absorption
- Enhanced Cognitive Function
- Reduced Anxiety and Depression
- Improved Mood
- Enhancement of immune system
- Reduced Inflammation
- Blood Sugar & Weight Management



Significant opportunity for an effective, evidenced based OTC IBS product



IBS is a highly prevalent issue with a large addressable market:

- **11%** of the global population have IBS.
- **37m** people in the US and **~3m in Aust** have IBS.
- **\$23.4B** digestive health market in 2030.

Debilitating Symptoms

- Patients experience pain, bloating & diarrhoea.

Limited Treatments

- Pharmacological options remain limited and often leave patients with poorly controlled symptoms.

OTC is Preferred Treatment Method:

- **77%** of individuals with IBS have used OTC treatment for IBS symptoms.
- **15%** of individuals with IBS have used prescription medications.


The current IBS treatments have low treatment satisfaction:

- **15%** of IBS-C sufferers were 'very satisfied' with OTC treatments.
- **20%** of IBS-D sufferers were 'very satisfied' with OTC treatments.

GaRP Stage 1 Clinical Trial Data

- Randomised, double-blind, placebo-controlled study (n = 61)
- Primary Endpoint:
 - a. 56% Reduction in internationally recognised Irritable Bowel Severity Scoring System (IBS-SSS) (Primary Endpoint).
- Secondary Endpoints:
 - b. 31% Reduction in Hospital Anxiety & Depression Score.
 - c. 22% Reduction in IBS Quality of Life Score.
- Data Safety Monitoring Board has recommended that the Company should proceed with Stage 2.

Reduction in IBS-SSS Score - Placebo vs. Low & High Dose



Disclaimer

This document has been prepared by Anantara Lifesciences (ABN 41 145 239 872) and Candour Advisory Limited (ABN 64 628 454 839). While the information contained in this Fact Sheet has been prepared with all reasonable care from sources which the Advisors believe are reliable, no guarantee is given that the information is accurate or complete. The Advisors, its directors and/or employees, make no recommendation nor do they make any recommendation or warranty to you concerning the accuracy, reliability or completeness of the information provided or the performance of the Company. The information is confidential.



Candour Advisory Pty Ltd, its associated entities and its personnel of same, hold or may hold securities in the companies/trusts mentioned herein. Candour may have also received corporate fees for any companies/trusts mentioned herein. To the extent permitted by law we exclude all liability for any direct, indirect and consequential costs, losses, damages and expenses incurred in any way, connected with any use or access to this document or any reliance on information contained in this email or any attachments. Candour Advisory Pty Ltd ABN 64 628 454 839 is a Corporate Authorised Representative No. 001305071 of SA Capital Pty Ltd ABN 78 114 959 803 AFSL No. 291787





Contact Us

ANATARA LIFESCIENCES LTD

David Brookes

Executive Chair

+61 0411 712 579

www.anataralifesciences.com

Dirk van Dissel

Investor Relations

Candour Advisory

dirk@candouradvisory.com.au

